Delafloxacin

Delafloxacin
Delafloxacin
Chemical compound
IUPAC	1- (6-amino-3,5-difluoro-2-pyridyl) -8-chloro-6-fluoro-7- (3-hydroxyazetidin-1-yl) -4-oxo-quinoline-3-carboxylic acid
Gross formula	C 18 H 12 ClF 3 N 4 O 4
Molar mass	440.76 g / mol
Cas
PubChem
Drugbank
Route of administration
	Oral , intravenous injection
Other names
	Baxdela

Delafloxacin is an antibiotic from the group of fluoroquinolones for the treatment of acute bacterial infections of the skin and skin structures. Approved for use: USA (2017) ^[1] ^[2] .

Content

1 mechanism of action
2 Indications
3 side effects
4 Contraindications
5 notes

Mechanism of Action

Inhibits DNA gyrase and topoisomerase IV ^[3] .

Indications

Treatment of acute bacterial infections of the skin and skin structures in adults caused by gram-positive microorganisms ^[4] :

Gram-positive bacteria : Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus ), Staphylococcus haemolyticus , Staphylococcus lugdunensis , Streptococcus agalactiae , Streptococcus anginosus ( Streptococcus anginosus , Streptocococcus streptococcus , Streptococcus Streptococcus Streptococcus Streptococcus , Streptococcus streptococcus , Streptococcus streptococcus , Streptococcus anthococcus , Streptococcus anthococcus
Gram-negative bacteria : Escherichia coli , Enterobacter cloacae , Klebsiella pneumoniae , Pseudomonas aeruginosa .

Side Effects

The most common: nausea, vomiting, diarrhea, headache.
More rare and serious: taking delafloxacin can be associated with the development of serious side effects, such as tendonitis and tendon rupture, peripheral neuropathy and disorders of the central nervous system ^[5] .

Contraindications

hypersensitivity to the drug.

Notes

↑ Novel Drug Approvals for 2017 . FDA
↑ Delafloxacin for the treatment of respiratory and skin infections. (eng.) .
↑ Delafloxacin: design, development and potential place in therapy .
↑ Drugs @ FDA: FDA Approved Drug Products . FDA
↑ FDA approved the new antibacterial drug delafloxacin (delafloxacin) by Melinta Therapeutics (Russian) .

[1] Novel Drug Approvals for 2017 . FDA

[2] Delafloxacin for the treatment of respiratory and skin infections. (eng.) .

[3] Delafloxacin: design, development and potential place in therapy .

[4] Drugs @ FDA: FDA Approved Drug Products . FDA

[5] FDA approved the new antibacterial drug delafloxacin (delafloxacin) by Melinta Therapeutics (Russian) .